CorVel Announces Effectiveness of Three-For-One Forward Stock Split 
Lexaria’s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024...
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
Poster presented at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)Primary analysis data in potentially pivotal GBM...
S4 Medical Receives FDA 510(k) Approval for its Redesigned Esophageal Deviation Device and Begins Commercialization
CHAGRIN FALLS, OH / ACCESSWIRE / November 25, 2024 / S4 Medical Corp, an Ohio based company committed to making...
Acreage Provides Update on Corporate Transactions
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Acreage Holdings, Inc. ("Acreage" or the "Company") (CSE:ACRG.A.U, ACRG.B.U)(OTCQX:ACRHF, ACRDF),...
Moderna to Present at Upcoming Conferences in December 2024
CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming...
Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution
New artificial intelligence (AI) capabilities help hospitals and health systems deliver safer and more efficient care Teladoc Health's AI-enabled Virtual...
MDxHealth to Participate in Piper Sandler Healthcare Conference
MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH)...
Spinogenix Appoints American Football Hall of Famer and Health Advocate Steve Young to its Board of Directors
LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses...
QHSLab, Inc. (OTCQB: USAQ) Marks Major Achievements in Digital Health Innovation, Research Recognition, and Revenue Growth in 2024
Revenue Growth and APA Recognition Drive Momentum for QHSLab in 2024 WEST PALM BEACH, FL, Nov. 25, 2024 (GLOBE NEWSWIRE)...
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS...
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address...
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns
HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology...
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in cell therapies, today announced...
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd....
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule,...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial ExecutionCORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst...
Recludix Pharma to Participate in Two Investor Conferences in December
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for...
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
PHILADELPHIA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage immunotherapy company specializing in the development of innovative cell therapies...